BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.

NCT06598722 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

206

Enrollment

OTHER

Sponsor class

Conditions

Lymphoblastic Lymphoma, Adult
Lymphoblastic Leukemia, Acute T-cell

Interventions

DRUG: BCL-2 inhibitors combined with the HyperCVAD regimen
OTHER: Propensity score matching historical data

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine